In the BioHarmony Drug Report Database
Braftovi (encorafenib) is a small molecule pharmaceutical. Encorafenib was first approved as Braftovi on 2018-06-27. It is used to treat melanoma in the USA. It has been approved in Europe to treat colorectal neoplasms and melanoma. Braftovi’s patents are valid until 2033-08-05 (FDA).
Image (chem structure or protein)